Standout Papers

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec i... 2017 2026 2020 2023 461
  1. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma (2017)
    Jason Chesney, Igor Puzanov et al. Journal of Clinical Oncology

Immediate Impact

2 by Nobel laureates 7 from Science/Nature 66 standout
Sub-graph 1 of 21

Citing Papers

Natural killer cell therapies
2024 StandoutNature
Principles and therapeutic applications of adaptive immunity
2024 Standout
5 intermediate papers

Works of Parminder Singh being referenced

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
2019
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
2017 Standout

Author Peers

Author Last Decade Papers Cites
Parminder Singh 758 257 257 431 339 102 1.5k
Keisuke Watanabe 1035 204 148 582 435 122 2.1k
Takahiro Tsujimura 712 193 344 461 197 95 2.1k
João L. Ascensão 524 163 162 334 372 64 1.8k
Tony R. Reid 1064 300 184 674 584 65 2.1k
Laura Pala 1270 506 259 331 162 66 2.0k
Jörn Gröne 425 122 582 486 210 64 1.5k
Isamu Ishiwata 341 173 302 680 170 143 1.9k
Elimelech Okon 375 241 297 335 139 72 1.7k
Belinda R. Avalos 758 120 102 379 299 95 2.1k
Agnese Proietti 416 302 402 421 155 82 1.8k

All Works

Loading papers...

Rankless by CCL
2026